Clinical trials: Specific Advanced Solid Tumors
Locally Advanced Carcinoma, Metastatic Cancer
Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer
The aims of this study are to evaluate the efficacy of comprehensive genomic tumour profiling (CGP) from liquid and/or tissue biopsy in patients with locally advanced and/or metastatic solid cancer.
- Trial name
- SOUND (NCT05032092)
- Testing
- Next Generation Sequencing, Biomarker Monitoring
- Where
- 6 sites in Austria
- Volunteers
- 235 people
- Sponsor
- Medical University of Graz
Solid Tumor, Solid Carcinoma
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.
- Conditions
- Solid Tumor, Solid Carcinoma, Advanced Solid Tumor, Unresectable Solid Tumor
- Trial name
- NCT07638371
- Testing
- MSK-TCR5
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors
RATIONALE: The Chinese herb Huang Lian contains ingredients that may slow the growth of cancer cells and may be an effective treatment for solid tumors.
- Trial name
- NCT00014378
- Testing
- Chinese Herb Huanglian (Coptis chinesis)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumor, Solid
A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors
The goal of this clinical trial is to learn if tumor neoantigen-specific T cells can treat patients with advanced solid tumors. The main questions it aims to answer are: Evaluate the safety of intravenous infusion of tumor…
- Trial name
- Neoantigen-T (NCT06431529)
- Testing
- tumor neoantigen specific T cell
- Where
- China
- Volunteers
- 6 people
- Sponsor
- JIANG LONGWEI
Soft Tissue Sarcoma (STS), Osteosarcoma
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
The primary objective of this trial is to evaluate the safety and tolerability of the tumor neoantigen vaccine (SarcVac) in combination with a PD-1 antibody, with or without tumor-specific lymphocytes, in patients with advanced…
- Trial name
- NCT07648069
- Testing
- Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody, Neoantigen vaccine + anti-PD1 antibody
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sun Yat-sen University
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT04842630
- Testing
- SHR-1916
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of lurtotecan liposome in treating patients who have…
- Trial name
- NCT00003891
- Testing
- lurtotecan liposome
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- NCIC Clinical Trials Group
Unspecified Adult Solid Tumor, Protocol Specific
MG98 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MG98 in treating patients who have advanced solid tumors.
- Trial name
- NCT00003890
- Testing
- MG 98
- Where
- 2 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with ABI-007 may kill more tumor cells.
- Trial name
- NCT00095914
- Testing
- paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00307255
- Testing
- gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
This phase I trial is studying the side effects and the best dose of entinostat when given together with sorafenib tosylate in treating patients with advanced or metastatic solid tumors or refractory or relapsed acute myeloid…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01159301
- Testing
- entinostat, sorafenib tosylate, pharmacological study
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04442126
- Testing
- NM21-1480
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 52 people
- Sponsor
- Numab Therapeutics AG
Unspecified Adult Solid Tumor, Protocol Specific
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of Ro 31-7453 in treating patients who have locally…
- Trial name
- NCT00003755
- Testing
- MKC-1
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced…
- Trial name
- NCT00390117
- Testing
- CDKI AT7519, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Chronic Myeloproliferative Disorders, Leukemia
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003082
- Testing
- monoclonal antibody A27.15, monoclonal antibody E2.3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Arizona
Unspecified Adult Solid Tumor, Protocol Specific
BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006086
- Testing
- BMS-188797, carboplatin
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Unspecified Adult Solid Tumor, Protocol Specific
Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of anhydrovinblastine in treating patients who have…
- Trial name
- NCT00003882
- Testing
- anhydrovinblastine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
RATIONALE: Collecting and storing samples of tissue or blood from patients with cancer for study in the laboratory may help the study of cancer in the future PURPOSE: This research study is collecting and storing blood and tissue…
- Trial name
- NCT00900471
- Testing
- biologic sample preservation procedure, medical chart review
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Wake Forest University Health Sciences
Unspecified Adult Solid Tumor, Protocol Specific
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00714181
- Testing
- hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors
Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors
multi-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer (mCRPC) and in advanced/metastatic solid tumors…
- Trial name
- BASKET PSMA (NCT03453528)
- Testing
- 68Ga-PSMA
- Where
- Italy
- Volunteers
- 1,225 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS